São Carlos Empreendimentos e Participações Valuation
Is SCAR3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SCAR3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SCAR3's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SCAR3's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SCAR3?
Other financial metrics that can be useful for relative valuation.
| What is SCAR3's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | R$1.26b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | -106.3x |
| Enterprise Value/EBITDA | -77x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does SCAR3's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 17.8x | ||
LAND3 Terra Santa Propriedades Agrícolas | 43.3x | n/a | R$1.2b |
SYNE3 Syn Prop & Tech | 2.8x | -80.5% | R$1.3b |
LOGG3 LOG Commercial Properties e Participações | 6.2x | -15.5% | R$2.0b |
JHSF3 JHSF Participações | 18.7x | 77.2% | R$3.1b |
SCAR3 São Carlos Empreendimentos e Participações | 5.1x | n/a | R$1.3b |
Price-To-Earnings vs Peers: SCAR3 is good value based on its Price-To-Earnings Ratio (5.1x) compared to the peer average (17.8x).
Price to Earnings Ratio vs Industry
How does SCAR3's PE Ratio compare vs other companies in the South American Real Estate Industry?
Price-To-Earnings vs Industry: SCAR3 is good value based on its Price-To-Earnings Ratio (5.1x) compared to the South American Real Estate industry average (9.1x).
Price to Earnings Ratio vs Fair Ratio
What is SCAR3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 5.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SCAR3's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | R$21.84 | R$28.50 +30.5% | 1.8% | R$29.00 | R$28.00 | n/a | 2 |
| Oct ’25 | R$22.51 | R$28.50 +26.6% | 1.8% | R$29.00 | R$28.00 | n/a | 2 |
| Sep ’25 | R$24.80 | R$31.00 +25.0% | 9.1% | R$35.00 | R$29.00 | n/a | 3 |
| Aug ’25 | R$24.28 | R$32.00 +31.8% | 9.4% | R$35.00 | R$29.00 | n/a | 2 |
| Jul ’25 | R$22.90 | R$37.00 +61.6% | 20.2% | R$47.00 | R$29.00 | n/a | 3 |
| Jun ’25 | R$25.90 | R$37.00 +42.9% | 20.2% | R$47.00 | R$29.00 | n/a | 3 |
| May ’25 | R$27.74 | R$37.00 +33.4% | 20.2% | R$47.00 | R$29.00 | n/a | 3 |
| Apr ’25 | R$27.20 | R$37.00 +36.0% | 20.2% | R$47.00 | R$29.00 | n/a | 3 |
| Mar ’25 | R$25.76 | R$37.00 +43.6% | 20.2% | R$47.00 | R$29.00 | n/a | 3 |
| Feb ’25 | R$27.50 | R$37.00 +34.5% | 20.2% | R$47.00 | R$29.00 | n/a | 3 |
| Jan ’25 | R$27.50 | R$37.00 +34.5% | 20.2% | R$47.00 | R$29.00 | n/a | 3 |
| Dec ’24 | R$24.79 | R$37.00 +49.3% | 20.2% | R$47.00 | R$29.00 | n/a | 3 |
| Nov ’24 | R$24.02 | R$37.00 +54.0% | 20.2% | R$47.00 | R$29.00 | R$22.02 | 3 |
| Oct ’24 | R$26.20 | R$37.00 +41.2% | 20.2% | R$47.00 | R$29.00 | R$22.51 | 3 |
| Sep ’24 | R$24.06 | R$37.00 +53.8% | 20.2% | R$47.00 | R$29.00 | R$24.80 | 3 |
| Aug ’24 | R$26.35 | R$37.00 +40.4% | 20.2% | R$47.00 | R$29.00 | R$24.28 | 3 |
| Jul ’24 | R$21.45 | R$37.00 +72.5% | 20.2% | R$47.00 | R$29.00 | R$22.90 | 3 |
| Jun ’24 | R$19.60 | R$37.00 +88.8% | 20.2% | R$47.00 | R$29.00 | R$25.90 | 3 |
| May ’24 | R$16.39 | R$38.25 +133.4% | 17.9% | R$47.00 | R$29.00 | R$27.74 | 4 |
| Apr ’24 | R$14.87 | R$38.25 +157.2% | 17.9% | R$47.00 | R$29.00 | R$27.20 | 4 |
| Mar ’24 | R$11.82 | R$38.40 +224.9% | 15.9% | R$47.00 | R$29.00 | R$25.76 | 5 |
| Feb ’24 | R$15.04 | R$38.40 +155.3% | 15.9% | R$47.00 | R$29.00 | R$27.50 | 5 |
| Jan ’24 | R$18.15 | R$38.40 +111.6% | 15.9% | R$47.00 | R$29.00 | R$27.50 | 5 |
| Dec ’23 | R$24.50 | R$38.40 +56.7% | 15.9% | R$47.00 | R$29.00 | R$24.79 | 5 |
| Nov ’23 | R$27.57 | R$41.40 +50.2% | 10.0% | R$47.00 | R$35.00 | R$24.02 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.